Evidence map›Paper›PMID 42248661›Full record

ArticleLife science alliance2026

GPLD1 is a scavenger carrier mediating lysosomal degradation of extracellular aberrant proteins.

Mizuki Tsuchiya, Yoichiro Yagishita, Eisuke Itakura

Abstract read
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mizuki TsuchiyaDepartment of Biology, Graduate School of Science and Engineering, Chiba University, Chiba, Japan.
Yoichiro YagishitaDepartment of Biology, Faculty of Science, Chiba University, Chiba, Japan.
Eisuke ItakuraDepartment of Biology, Graduate School of Science, Chiba University, Chiba, Japan eitakura@chiba-u.jp.ORCID https://orcid.org/0000-0001-7248-9333

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of proteostasis leads to the accumulation of aberrant proteins, including aggregated proteins and amyloid fibrils, contributing to various diseases. Protein quality control systems are essential for maintaining proteostasis. Although intracellular mechanisms are well characterized, pathways responsible for the degradation of aberrant proteins outside the cell remain poorly understood. We previously identified the chaperone/carrier- and receptor-mediated extracellular protein degradation pathway, in which the extracellular chaperone clusterin binds misfolded proteins and the resulting complex is delivered to lysosomes via endocytosis. However, it remains unclear whether other factors are involved in this pathway. To identify novel regulators, plasma factors binding serum amyloid A1 were investigated. Glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) was found to directly bind serum amyloid A1 and promote its lysosomal degradation. This activity was independent of GPLD1's cleavage activity for GPI-anchored proteins. Furthermore, GPLD1 mediates lysosomal degradation of misfolded proteins, with cell surface heparan sulfate acting as its receptor. Our data demonstrate that GPLD1 is a novel scavenger carrier with substrate specificity distinct from clusterin, responsible for degrading extracellular aberrant proteins.

Indexed as

LysosomesAnimalsClusterinEndocytosisHEK293 CellsHumansProtein BindingProteolysisProteostasisClusterin

Identifiers

PMID42248661
PMCPMC13241479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.